Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

695
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
695
Drugs Affecting GI Tract Motility: Other Laxatives01:20

Drugs Affecting GI Tract Motility: Other Laxatives

1.1K
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
1.1K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

1.3K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.3K
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

227
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
227
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

1.7K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.7K
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

994
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
994

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of systemic lupus erythematosus with 90-day readmission following heart failure hospitalization: A national readmission database (NRD) analysis, 2016-2017.

Lupus·2026
Same author

Phase-Separated Condensates of Atomically Precise Nanoclusters Enable Direct Visualization of Nano-Bio Interactions.

ACS nano·2026
Same author

Emerging encapsulation techniques for controlled and targeted delivery of bioactive compounds in food and nutraceutical systems.

Frontiers in nutrition·2026
Same author

Pseudoaneurysm of the Medial Femoral Circumflex Artery following Surgical Fixation of Trochanteric Femur Fracture: A Case Report.

Journal of orthopaedic case reports·2026
Same author

WZB117-Induced Glucose Hypometabolism Triggers Mitochondrial Dysfunction and Amyloidogenic Processing in an In Vitro Primary Forebrain Neuron Model.

Cureus·2026
Same author

Improved magnetorheological finishing of a 3D K9 glass surface for ultra-precision optical applications.

Applied optics·2026

Related Experiment Video

Updated: Feb 17, 2026

Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer
08:47

Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer

Published on: April 21, 2022

3.9K

Small Molecules as Modulators to Prevent Mucin Aggregation via Delaying Liquid-to-Solid Phase Transition.

Komal Kumari1, Anant Kumar Singh1, Surajit Rakshit1

  • 1Department of Chemistry, Institute of Science, Banaras Hindu University, Varanasi, Uttar Pradesh 221005, India.

The Journal of Physical Chemistry Letters
|February 16, 2026
PubMed
Summary
This summary is machine-generated.

Aberrant mucin aggregation in mucosal disorders can be suppressed by bioactive compounds. Scopolamine, Quercetin, and Epigallocatechin-3-gallate show potential in modulating mucin aggregation and associated pathologies.

More Related Videos

Mucin Agarose Gel Electrophoresis: Western Blotting for High-molecular-weight Glycoproteins
09:24

Mucin Agarose Gel Electrophoresis: Western Blotting for High-molecular-weight Glycoproteins

Published on: June 14, 2016

27.1K
Using Unfixed, Frozen Tissues to Study Natural Mucin Distribution
11:39

Using Unfixed, Frozen Tissues to Study Natural Mucin Distribution

Published on: September 21, 2012

48.6K

Related Experiment Videos

Last Updated: Feb 17, 2026

Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer
08:47

Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer

Published on: April 21, 2022

3.9K
Mucin Agarose Gel Electrophoresis: Western Blotting for High-molecular-weight Glycoproteins
09:24

Mucin Agarose Gel Electrophoresis: Western Blotting for High-molecular-weight Glycoproteins

Published on: June 14, 2016

27.1K
Using Unfixed, Frozen Tissues to Study Natural Mucin Distribution
11:39

Using Unfixed, Frozen Tissues to Study Natural Mucin Distribution

Published on: September 21, 2012

48.6K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pathophysiology

Background:

  • Aberrant mucin aggregation is implicated in various mucosal disorders.
  • The molecular mechanisms driving mucin aggregation under physiological conditions are not fully understood.
  • Mucin solubility is sensitive to calcium concentration, pH, and macromolecular crowding.

Purpose of the Study:

  • To investigate the molecular determinants of mucin aggregation under physiologically relevant conditions.
  • To evaluate the inhibitory effects of Scopolamine (SCP), Quercetin (QUE), and Epigallocatechin-3-gallate (EPGG) on mucin aggregation.
  • To elucidate the mechanisms by which these bioactive compounds modulate mucin aggregation.

Main Methods:

  • Systematic investigation of mucin aggregation under various stressors.
  • Evaluation of the concentration and time-dependent effects of SCP, QUE, and EPGG.
  • Analysis of condensate morphology and internal molecular dynamics.
  • Permeability profiling of bioactive compounds.

Main Results:

  • All three tested bioactives (SCP, QUE, EPGG) suppressed mucin aggregation in a concentration- and time-dependent manner.
  • SCP demonstrated efficacy via electrostatic competition under acidic conditions.
  • QUE and EPGG inhibited aggregation through hydrogen bonding and hydrophobic interactions.
  • Bioactives reduced internal molecular dynamics without altering condensate morphology.
  • SCP was identified as a systemically accessible modulator.

Conclusions:

  • Bioactive compounds can effectively suppress aberrant mucin aggregation.
  • Distinct mechanisms of action were identified for SCP, QUE, and EPGG.
  • Small-molecule bioactives represent promising therapeutic agents for mucin-associated pathologies.
  • SCP shows potential as a systemically administrable therapeutic modulator.